ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Angiogenesis Therapeutic Agent Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-23E14157
Home | Market Reports | Health| Health Conditions| Cancer
Global Angiogenesis Therapeutic Agent Market Research Report 2023
BUY CHAPTERS

Global Angiogenesis Therapeutic Agent Market Research Report 2025

Code: QYRE-Auto-23E14157
Report
May 2025
Pages:104
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Gilead Sciences Inc
Eyetech
Becton Dickinson and Company
Regeneron Pharmaceuticals Inc
Genentech Inc
Novartis
Allergan plc
Bayer
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer Inc
Sun Pharma
Otsuka Pharmaceutical Co Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
The Geuder Group, MORCHER GmbH
Novamedika
Implandata ophthalmic products GmbH

Angiogenesis Therapeutic Agent Market

The global market for Angiogenesis Therapeutic Agent was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
North American market for Angiogenesis Therapeutic Agent is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Angiogenesis Therapeutic Agent is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Angiogenesis Therapeutic Agent include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Angiogenesis Therapeutic Agent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Therapeutic Agent.
The Angiogenesis Therapeutic Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Angiogenesis Therapeutic Agent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Angiogenesis Therapeutic Agent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Angiogenesis Therapeutic Agent Market Report

Report Metric Details
Report Name Angiogenesis Therapeutic Agent Market
Segment by Type
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Diabetic Retinopathy
  • Macular Degeneration
Segment by Application
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, Johnson & Johnson, Pfizer, Sun Pharma, Otsuka Pharmaceutical Co. Ltd, Daiichi Sankyo, ERC Labs, Medicom Health care, Implandata ophthalmic products GmbH, The Geuder Group, MORCHER GmbH, Novamedika
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Angiogenesis Therapeutic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Angiogenesis Therapeutic Agent Market report?

Ans: The main players in the Angiogenesis Therapeutic Agent Market are Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, Johnson & Johnson, Pfizer, Sun Pharma, Otsuka Pharmaceutical Co. Ltd, Daiichi Sankyo, ERC Labs, Medicom Health care, Implandata ophthalmic products GmbH, The Geuder Group, MORCHER GmbH, Novamedika

What are the Application segmentation covered in the Angiogenesis Therapeutic Agent Market report?

Ans: The Applications covered in the Angiogenesis Therapeutic Agent Market report are Retail Pharmacies, Online Pharmacies, Hospital Pharmacies

What are the Type segmentation covered in the Angiogenesis Therapeutic Agent Market report?

Ans: The Types covered in the Angiogenesis Therapeutic Agent Market report are Myopic Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy, Macular Degeneration

1 Angiogenesis Therapeutic Agent Market Overview
1.1 Product Definition
1.2 Angiogenesis Therapeutic Agent by Type
1.2.1 Global Angiogenesis Therapeutic Agent Market Value Comparison by Type (2024 VS 2031)
1.2.2 Myopic Choroidal Neovascularization
1.2.3 Macular Edema
1.2.4 Diabetic Retinopathy
1.2.5 Macular Degeneration
1.3 Angiogenesis Therapeutic Agent by Application
1.3.1 Global Angiogenesis Therapeutic Agent Market Value by Application (2024 VS 2031)
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.3.4 Hospital Pharmacies
1.4 Global Angiogenesis Therapeutic Agent Market Size Estimates and Forecasts
1.4.1 Global Angiogenesis Therapeutic Agent Revenue 2020-2031
1.4.2 Global Angiogenesis Therapeutic Agent Sales 2020-2031
1.4.3 Global Angiogenesis Therapeutic Agent Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Angiogenesis Therapeutic Agent Market Competition by Manufacturers
2.1 Global Angiogenesis Therapeutic Agent Sales Market Share by Manufacturers (2020-2025)
2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Angiogenesis Therapeutic Agent Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Angiogenesis Therapeutic Agent, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Product Type & Application
2.7 Global Key Manufacturers of Angiogenesis Therapeutic Agent, Date of Enter into This Industry
2.8 Global Angiogenesis Therapeutic Agent Market Competitive Situation and Trends
2.8.1 Global Angiogenesis Therapeutic Agent Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Angiogenesis Therapeutic Agent Players Market Share by Revenue
2.8.3 Global Angiogenesis Therapeutic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Angiogenesis Therapeutic Agent Market Scenario by Region
3.1 Global Angiogenesis Therapeutic Agent Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Angiogenesis Therapeutic Agent Sales by Region: 2020-2031
3.2.1 Global Angiogenesis Therapeutic Agent Sales by Region: 2020-2025
3.2.2 Global Angiogenesis Therapeutic Agent Sales by Region: 2026-2031
3.3 Global Angiogenesis Therapeutic Agent Revenue by Region: 2020-2031
3.3.1 Global Angiogenesis Therapeutic Agent Revenue by Region: 2020-2025
3.3.2 Global Angiogenesis Therapeutic Agent Revenue by Region: 2026-2031
3.4 North America Angiogenesis Therapeutic Agent Market Facts & Figures by Country
3.4.1 North America Angiogenesis Therapeutic Agent Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Angiogenesis Therapeutic Agent Sales by Country (2020-2031)
3.4.3 North America Angiogenesis Therapeutic Agent Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Angiogenesis Therapeutic Agent Market Facts & Figures by Country
3.5.1 Europe Angiogenesis Therapeutic Agent Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Angiogenesis Therapeutic Agent Sales by Country (2020-2031)
3.5.3 Europe Angiogenesis Therapeutic Agent Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Angiogenesis Therapeutic Agent Market Facts & Figures by Region
3.6.1 Asia Pacific Angiogenesis Therapeutic Agent Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Angiogenesis Therapeutic Agent Sales by Region (2020-2031)
3.6.3 Asia Pacific Angiogenesis Therapeutic Agent Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Angiogenesis Therapeutic Agent Market Facts & Figures by Country
3.7.1 Latin America Angiogenesis Therapeutic Agent Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Angiogenesis Therapeutic Agent Sales by Country (2020-2031)
3.7.3 Latin America Angiogenesis Therapeutic Agent Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Angiogenesis Therapeutic Agent Market Facts & Figures by Country
3.8.1 Middle East and Africa Angiogenesis Therapeutic Agent Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2020-2031)
3.8.3 Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Angiogenesis Therapeutic Agent Sales by Type (2020-2031)
4.1.1 Global Angiogenesis Therapeutic Agent Sales by Type (2020-2025)
4.1.2 Global Angiogenesis Therapeutic Agent Sales by Type (2026-2031)
4.1.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2020-2031)
4.2 Global Angiogenesis Therapeutic Agent Revenue by Type (2020-2031)
4.2.1 Global Angiogenesis Therapeutic Agent Revenue by Type (2020-2025)
4.2.2 Global Angiogenesis Therapeutic Agent Revenue by Type (2026-2031)
4.2.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2020-2031)
4.3 Global Angiogenesis Therapeutic Agent Price by Type (2020-2031)
5 Segment by Application
5.1 Global Angiogenesis Therapeutic Agent Sales by Application (2020-2031)
5.1.1 Global Angiogenesis Therapeutic Agent Sales by Application (2020-2025)
5.1.2 Global Angiogenesis Therapeutic Agent Sales by Application (2026-2031)
5.1.3 Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2020-2031)
5.2 Global Angiogenesis Therapeutic Agent Revenue by Application (2020-2031)
5.2.1 Global Angiogenesis Therapeutic Agent Revenue by Application (2020-2025)
5.2.2 Global Angiogenesis Therapeutic Agent Revenue by Application (2026-2031)
5.2.3 Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2020-2031)
5.3 Global Angiogenesis Therapeutic Agent Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Gilead Sciences, Inc.
6.1.1 Gilead Sciences, Inc. Company Information
6.1.2 Gilead Sciences, Inc. Description and Business Overview
6.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolio
6.1.5 Gilead Sciences, Inc. Recent Developments/Updates
6.2 Eyetech Inc.
6.2.1 Eyetech Inc. Company Information
6.2.2 Eyetech Inc. Description and Business Overview
6.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolio
6.2.5 Eyetech Inc. Recent Developments/Updates
6.3 Becton, Dickinson and Company
6.3.1 Becton, Dickinson and Company Company Information
6.3.2 Becton, Dickinson and Company Description and Business Overview
6.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolio
6.3.5 Becton, Dickinson and Company Recent Developments/Updates
6.4 Regeneron Pharmaceuticals, Inc.
6.4.1 Regeneron Pharmaceuticals, Inc. Company Information
6.4.2 Regeneron Pharmaceuticals, Inc. Description and Business Overview
6.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolio
6.4.5 Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
6.5 Genentech, Inc.
6.5.1 Genentech, Inc. Company Information
6.5.2 Genentech, Inc. Description and Business Overview
6.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolio
6.5.5 Genentech, Inc. Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Company Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis AG Angiogenesis Therapeutic Agent Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Allergan plc
6.7.1 Allergan plc Company Information
6.7.2 Allergan plc Description and Business Overview
6.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Allergan plc Angiogenesis Therapeutic Agent Product Portfolio
6.7.5 Allergan plc Recent Developments/Updates
6.8 Bayer AG
6.8.1 Bayer AG Company Information
6.8.2 Bayer AG Description and Business Overview
6.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Portfolio
6.8.5 Bayer AG Recent Developments/Updates
6.9 Santen Pharmaceutical Co., Ltd.
6.9.1 Santen Pharmaceutical Co., Ltd. Company Information
6.9.2 Santen Pharmaceutical Co., Ltd. Description and Business Overview
6.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolio
6.9.5 Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
6.10 Shanghai Pharmaceuticals
6.10.1 Shanghai Pharmaceuticals Company Information
6.10.2 Shanghai Pharmaceuticals Description and Business Overview
6.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolio
6.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.11 Johnson & Johnson
6.11.1 Johnson & Johnson Company Information
6.11.2 Johnson & Johnson Description and Business Overview
6.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolio
6.11.5 Johnson & Johnson Recent Developments/Updates
6.12 Pfizer
6.12.1 Pfizer Company Information
6.12.2 Pfizer Description and Business Overview
6.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Pfizer Angiogenesis Therapeutic Agent Product Portfolio
6.12.5 Pfizer Recent Developments/Updates
6.13 Sun Pharma
6.13.1 Sun Pharma Company Information
6.13.2 Sun Pharma Description and Business Overview
6.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolio
6.13.5 Sun Pharma Recent Developments/Updates
6.14 Otsuka Pharmaceutical Co. Ltd
6.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
6.14.2 Otsuka Pharmaceutical Co. Ltd Description and Business Overview
6.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolio
6.14.5 Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
6.15 Daiichi Sankyo
6.15.1 Daiichi Sankyo Company Information
6.15.2 Daiichi Sankyo Description and Business Overview
6.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolio
6.15.5 Daiichi Sankyo Recent Developments/Updates
6.16 ERC Labs
6.16.1 ERC Labs Company Information
6.16.2 ERC Labs Description and Business Overview
6.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.16.4 ERC Labs Angiogenesis Therapeutic Agent Product Portfolio
6.16.5 ERC Labs Recent Developments/Updates
6.17 Medicom Health care
6.17.1 Medicom Health care Company Information
6.17.2 Medicom Health care Description and Business Overview
6.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolio
6.17.5 Medicom Health care Recent Developments/Updates
6.18 Implandata ophthalmic products GmbH
6.18.1 Implandata ophthalmic products GmbH Company Information
6.18.2 Implandata ophthalmic products GmbH Description and Business Overview
6.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolio
6.18.5 Implandata ophthalmic products GmbH Recent Developments/Updates
6.19 The Geuder Group, MORCHER GmbH
6.19.1 The Geuder Group, MORCHER GmbH Company Information
6.19.2 The Geuder Group, MORCHER GmbH Description and Business Overview
6.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.19.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolio
6.19.5 The Geuder Group, MORCHER GmbH Recent Developments/Updates
6.20 Novamedika
6.20.1 Novamedika Company Information
6.20.2 Novamedika Description and Business Overview
6.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Novamedika Angiogenesis Therapeutic Agent Product Portfolio
6.20.5 Novamedika Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Angiogenesis Therapeutic Agent Industry Chain Analysis
7.2 Angiogenesis Therapeutic Agent Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Angiogenesis Therapeutic Agent Production Mode & Process Analysis
7.4 Angiogenesis Therapeutic Agent Sales and Marketing
7.4.1 Angiogenesis Therapeutic Agent Sales Channels
7.4.2 Angiogenesis Therapeutic Agent Distributors
7.5 Angiogenesis Therapeutic Agent Customer Analysis
8 Angiogenesis Therapeutic Agent Market Dynamics
8.1 Angiogenesis Therapeutic Agent Industry Trends
8.2 Angiogenesis Therapeutic Agent Market Drivers
8.3 Angiogenesis Therapeutic Agent Market Challenges
8.4 Angiogenesis Therapeutic Agent Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Gilead Sciences Inc
Eyetech
Becton Dickinson and Company
Regeneron Pharmaceuticals Inc
Genentech Inc
Novartis
Allergan plc
Bayer
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer Inc
Sun Pharma
Otsuka Pharmaceutical Co Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
The Geuder Group, MORCHER GmbH
Novamedika
Implandata ophthalmic products GmbH
List of Tables
 Table 1. Global Angiogenesis Therapeutic Agent Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Angiogenesis Therapeutic Agent Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Angiogenesis Therapeutic Agent Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Angiogenesis Therapeutic Agent Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Angiogenesis Therapeutic Agent Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Angiogenesis Therapeutic Agent Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Angiogenesis Therapeutic Agent Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Angiogenesis Therapeutic Agent Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Angiogenesis Therapeutic Agent, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Product Type & Application
 Table 12. Global Key Manufacturers of Angiogenesis Therapeutic Agent, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Angiogenesis Therapeutic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Therapeutic Agent as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Angiogenesis Therapeutic Agent Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Angiogenesis Therapeutic Agent Sales by Region (2020-2025) & (K Units)
 Table 18. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2020-2025)
 Table 19. Global Angiogenesis Therapeutic Agent Sales by Region (2026-2031) & (K Units)
 Table 20. Global Angiogenesis Therapeutic Agent Sales Market Share by Region (2026-2031)
 Table 21. Global Angiogenesis Therapeutic Agent Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2020-2025)
 Table 23. Global Angiogenesis Therapeutic Agent Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Angiogenesis Therapeutic Agent Revenue Market Share by Region (2026-2031)
 Table 25. North America Angiogenesis Therapeutic Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Angiogenesis Therapeutic Agent Sales by Country (2020-2025) & (K Units)
 Table 27. North America Angiogenesis Therapeutic Agent Sales by Country (2026-2031) & (K Units)
 Table 28. North America Angiogenesis Therapeutic Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Angiogenesis Therapeutic Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Angiogenesis Therapeutic Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Angiogenesis Therapeutic Agent Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Angiogenesis Therapeutic Agent Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Angiogenesis Therapeutic Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Angiogenesis Therapeutic Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Angiogenesis Therapeutic Agent Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Angiogenesis Therapeutic Agent Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Angiogenesis Therapeutic Agent Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Angiogenesis Therapeutic Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Angiogenesis Therapeutic Agent Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Angiogenesis Therapeutic Agent Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Angiogenesis Therapeutic Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Angiogenesis Therapeutic Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Angiogenesis Therapeutic Agent Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Angiogenesis Therapeutic Agent Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Angiogenesis Therapeutic Agent Sales (K Units) by Type (2020-2025)
 Table 51. Global Angiogenesis Therapeutic Agent Sales (K Units) by Type (2026-2031)
 Table 52. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2020-2025)
 Table 53. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2026-2031)
 Table 54. Global Angiogenesis Therapeutic Agent Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Angiogenesis Therapeutic Agent Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2020-2025)
 Table 57. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2026-2031)
 Table 58. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Angiogenesis Therapeutic Agent Sales (K Units) by Application (2020-2025)
 Table 61. Global Angiogenesis Therapeutic Agent Sales (K Units) by Application (2026-2031)
 Table 62. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2020-2025)
 Table 63. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2026-2031)
 Table 64. Global Angiogenesis Therapeutic Agent Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Angiogenesis Therapeutic Agent Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2020-2025)
 Table 67. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2026-2031)
 Table 68. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Application (2026-2031)
 Table 70. Gilead Sciences, Inc. Company Information
 Table 71. Gilead Sciences, Inc. Description and Business Overview
 Table 72. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product
 Table 74. Gilead Sciences, Inc. Recent Developments/Updates
 Table 75. Eyetech Inc. Company Information
 Table 76. Eyetech Inc. Description and Business Overview
 Table 77. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Eyetech Inc. Angiogenesis Therapeutic Agent Product
 Table 79. Eyetech Inc. Recent Developments/Updates
 Table 80. Becton, Dickinson and Company Company Information
 Table 81. Becton, Dickinson and Company Description and Business Overview
 Table 82. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product
 Table 84. Becton, Dickinson and Company Recent Developments/Updates
 Table 85. Regeneron Pharmaceuticals, Inc. Company Information
 Table 86. Regeneron Pharmaceuticals, Inc. Description and Business Overview
 Table 87. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product
 Table 89. Regeneron Pharmaceuticals, Inc. Recent Developments/Updates
 Table 90. Genentech, Inc. Company Information
 Table 91. Genentech, Inc. Description and Business Overview
 Table 92. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Genentech, Inc. Angiogenesis Therapeutic Agent Product
 Table 94. Genentech, Inc. Recent Developments/Updates
 Table 95. Novartis AG Company Information
 Table 96. Novartis AG Description and Business Overview
 Table 97. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Novartis AG Angiogenesis Therapeutic Agent Product
 Table 99. Novartis AG Recent Developments/Updates
 Table 100. Allergan plc Company Information
 Table 101. Allergan plc Description and Business Overview
 Table 102. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Allergan plc Angiogenesis Therapeutic Agent Product
 Table 104. Allergan plc Recent Developments/Updates
 Table 105. Bayer AG Company Information
 Table 106. Bayer AG Description and Business Overview
 Table 107. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bayer AG Angiogenesis Therapeutic Agent Product
 Table 109. Bayer AG Recent Developments/Updates
 Table 110. Santen Pharmaceutical Co., Ltd. Company Information
 Table 111. Santen Pharmaceutical Co., Ltd. Description and Business Overview
 Table 112. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product
 Table 114. Santen Pharmaceutical Co., Ltd. Recent Developments/Updates
 Table 115. Shanghai Pharmaceuticals Company Information
 Table 116. Shanghai Pharmaceuticals Description and Business Overview
 Table 117. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product
 Table 119. Shanghai Pharmaceuticals Recent Developments/Updates
 Table 120. Johnson & Johnson Company Information
 Table 121. Johnson & Johnson Description and Business Overview
 Table 122. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Johnson & Johnson Angiogenesis Therapeutic Agent Product
 Table 124. Johnson & Johnson Recent Developments/Updates
 Table 125. Pfizer Company Information
 Table 126. Pfizer Description and Business Overview
 Table 127. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Pfizer Angiogenesis Therapeutic Agent Product
 Table 129. Pfizer Recent Developments/Updates
 Table 130. Sun Pharma Company Information
 Table 131. Sun Pharma Description and Business Overview
 Table 132. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Sun Pharma Angiogenesis Therapeutic Agent Product
 Table 134. Sun Pharma Recent Developments/Updates
 Table 135. Otsuka Pharmaceutical Co. Ltd Company Information
 Table 136. Otsuka Pharmaceutical Co. Ltd Description and Business Overview
 Table 137. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product
 Table 139. Otsuka Pharmaceutical Co. Ltd Recent Developments/Updates
 Table 140. Daiichi Sankyo Company Information
 Table 141. Daiichi Sankyo Description and Business Overview
 Table 142. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Daiichi Sankyo Angiogenesis Therapeutic Agent Product
 Table 144. Daiichi Sankyo Recent Developments/Updates
 Table 145. ERC Labs Company Information
 Table 146. ERC Labs Description and Business Overview
 Table 147. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. ERC Labs Angiogenesis Therapeutic Agent Product
 Table 149. ERC Labs Recent Developments/Updates
 Table 150. Medicom Health care Company Information
 Table 151. Medicom Health care Description and Business Overview
 Table 152. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Medicom Health care Angiogenesis Therapeutic Agent Product
 Table 154. Medicom Health care Recent Developments/Updates
 Table 155. Implandata ophthalmic products GmbH Company Information
 Table 156. Implandata ophthalmic products GmbH Description and Business Overview
 Table 157. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product
 Table 159. Implandata ophthalmic products GmbH Recent Developments/Updates
 Table 160. The Geuder Group, MORCHER GmbH Company Information
 Table 161. The Geuder Group, MORCHER GmbH Description and Business Overview
 Table 162. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product
 Table 164. The Geuder Group, MORCHER GmbH Recent Developments/Updates
 Table 165. Novamedika Company Information
 Table 166. Novamedika Description and Business Overview
 Table 167. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Novamedika Angiogenesis Therapeutic Agent Product
 Table 169. Novamedika Recent Developments/Updates
 Table 170. Key Raw Materials Lists
 Table 171. Raw Materials Key Suppliers Lists
 Table 172. Angiogenesis Therapeutic Agent Distributors List
 Table 173. Angiogenesis Therapeutic Agent Customers List
 Table 174. Angiogenesis Therapeutic Agent Market Trends
 Table 175. Angiogenesis Therapeutic Agent Market Drivers
 Table 176. Angiogenesis Therapeutic Agent Market Challenges
 Table 177. Angiogenesis Therapeutic Agent Market Restraints
 Table 178. Research Programs/Design for This Report
 Table 179. Key Data Information from Secondary Sources
 Table 180. Key Data Information from Primary Sources
 Table 181. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Angiogenesis Therapeutic Agent
 Figure 2. Global Angiogenesis Therapeutic Agent Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Angiogenesis Therapeutic Agent Market Share by Type: 2024 & 2031
 Figure 4. Myopic Choroidal Neovascularization Product Picture
 Figure 5. Macular Edema Product Picture
 Figure 6. Diabetic Retinopathy Product Picture
 Figure 7. Macular Degeneration Product Picture
 Figure 8. Global Angiogenesis Therapeutic Agent Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Angiogenesis Therapeutic Agent Market Share by Application: 2024 & 2031
 Figure 10. Retail Pharmacies
 Figure 11. Online Pharmacies
 Figure 12. Hospital Pharmacies
 Figure 13. Global Angiogenesis Therapeutic Agent Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Angiogenesis Therapeutic Agent Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Angiogenesis Therapeutic Agent Sales (2020-2031) & (K Units)
 Figure 16. Global Angiogenesis Therapeutic Agent Average Price (US$/Unit) & (2020-2031)
 Figure 17. Angiogenesis Therapeutic Agent Report Years Considered
 Figure 18. Angiogenesis Therapeutic Agent Sales Share by Manufacturers in 2024
 Figure 19. Global Angiogenesis Therapeutic Agent Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Angiogenesis Therapeutic Agent Players: Market Share by Revenue in Angiogenesis Therapeutic Agent in 2024
 Figure 21. Angiogenesis Therapeutic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Angiogenesis Therapeutic Agent Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Angiogenesis Therapeutic Agent Sales Market Share by Country (2020-2031)
 Figure 24. North America Angiogenesis Therapeutic Agent Revenue Market Share by Country (2020-2031)
 Figure 25. United States Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2020-2031)
 Figure 28. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Angiogenesis Therapeutic Agent Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Angiogenesis Therapeutic Agent Revenue Market Share by Region (2020-2031)
 Figure 36. China Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Angiogenesis Therapeutic Agent Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Angiogenesis Therapeutic Agent Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Angiogenesis Therapeutic Agent Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Angiogenesis Therapeutic Agent by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Angiogenesis Therapeutic Agent by Type (2020-2031)
 Figure 55. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Angiogenesis Therapeutic Agent by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Angiogenesis Therapeutic Agent by Application (2020-2031)
 Figure 58. Global Angiogenesis Therapeutic Agent Price (US$/Unit) by Application (2020-2031)
 Figure 59. Angiogenesis Therapeutic Agent Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Anti angiogenic Ophthalmic Agent Market Research Report 2024
Global Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Antiangiogenic Drugs Market Research Report 2024
Global Anti VEGF Ophthalmic Drug Market Research Report 2024
Global VEGF Inhibitors Market Research Report 2024
Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024
Global VEGF A Inhibitor Market Research Report 2024
Global Vascular Endothelial Growth Factor VEGF Inhibitors Market Insights Forecast to 2030
VEGF Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti VEGT Drugs Market Research Report 2024
Global VEGF Inhibitors for Cancer Market Research Report 2024
Global Anti VEGF Intravitreal Drugs Market Research Report 2024
Global Anti VEGF Therapy for Cancer Market Research Report 2024
Global Intravitreal Injection of Anti VEGF Drugs Market Research Report 2024
Global Anti Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025
Global Anti VEGF Therapeutic Market Research Report 2025
Global Fusion Protein Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Single target Anti VEGF Drugs Market Research Report 2024
Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global VEGFR 2 Inhibitor Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions